| 1.8 0.19 (11.8%) | 04-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.33 |
1-year : | 2.72 |
| Resists | First : | 2 |
Second : | 2.33 |
| Pivot price | 1.67 |
|||
| Supports | First : | 1.65 |
Second : | 1.44 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.7  |
| MA(100) : | 1.71 |
MA(250) : | 1.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 31.5 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 3.92 | Low : | 0.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MBAI ] has closed below upper band by 1.8%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.87 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.79 - 1.8 | 1.8 - 1.81 |
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.
Tue, 27 Jan 2026
Check-Cap (MBAI) Stock Price, News & Analysis - MarketBeat
Mon, 26 Jan 2026
GME Shares Surge Nearly 8% After Michael Burry Goes Long On Stock - Stocktwits
Mon, 26 Jan 2026
Penny Stock Check-Cap Has Nearly Doubled Its Value Today – What’s Going On With MBody AI Merger? - Stocktwits
Mon, 26 Jan 2026
Check-Cap Ltd. - Ordinary Share (Nasdaq:MBAI) Stock Quote - markets.chroniclejournal.com
Mon, 01 Dec 2025
Check-Cap ticker changes to MBAI as company shifts to embodied AI focus - investing.com
Mon, 17 Nov 2025
Check-Cap shareholders approve merger with MBody AI and company name change - investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 125 (K) |
| Shares Short P.Month | 271 (K) |
| EPS | -2.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -130.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 2.81 |
| Price to Sales | 0 |
| Price to Cash Flow | 166.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|